- The 8 States Most Likely to Legalize Marijuana Next
- Dow 18,000: Why This Market Rally May Never Happen Again
- BlackBerry Classic Review: A Bold Update for CrackBerry Fans
- Express Scripts and AbbVie Drug-Pricing Deal Might Devastate Biotech Bull Market
- Gilead Sciences Is Not a Buy; It's Heading Lower on Price War: Jim Cramer
U.S. regulators approved a new hepatitis C therapy from Abbvie, heralding a new era of market competition with Gilead Sciences.
European regulators recommended the approval of Orexigen Therapeutics weight-loss pill on Friday, opening a new commercial market opportunity closed off to the company's competitors.
One biotech CEO won accolades in 2010 only to be razzed for poor performance in 2011.
Tony Coles, the former CEO of Onyx sold to Amgen for $10 billion in late 2013, is launching Yumanity Therapeutics focused on developing drugs for neuro-degenerative diseases.
The re-acquisition of binimetinib by Array was expected after Novartis announced in April a business swap with GlaxoSmithKline GSK which included the acquisition of Glaxo's cancer drug business.
Wednesday's approval of Blincyto comes more than five months ahead of the expected May 19, 2015 approval decision date.
Puma Biotechnology is pushing back an approval filing for its breast cancer drug neratinib into 2016 -- almost a one year delay.
All too often, promising results from phase II studies don't pan out when larger, confirmatory phase III studies are conducted. That's exactly what happened to Exelixis.
The scandal-ridden Galena, still under active SEC investigation, was unable to muster sufficient interest from institutional investors.
The $3.3 billion paid by Royalty Pharma to the Cystic Fibrosis Foundation to acquire royalty rights to Vertex Pharmaceuticals' cystic fibrosis drugs suggests investors are under-estimating peak sales.